J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating on April 16.
Richard Vosser has given his Hold rating due to a combination of factors that suggest a stable outlook for Novartis AG. The company’s financial performance is expected to be slightly ahead of consensus, with forecasts indicating a modest increase in sales and core earnings per share. However, despite these positive indicators, the growth is not substantial enough to warrant a more bullish rating.
Moreover, while Novartis is projected to reiterate its guidance for sales and operating profit growth, the improvements are largely attributed to favorable foreign exchange conditions rather than significant operational advancements. Additionally, the performance of key products is mixed, with some exceeding expectations and others falling short. These elements combined lead to a balanced view, justifying the Hold rating as the stock is anticipated to perform in line with the market.
According to TipRanks, Vosser is a 3-star analyst with an average return of 2.1% and a 46.51% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and Molecular Partners AG.
In another report released on April 16, Bank of America Securities also reiterated a Hold rating on the stock with a CHF114.00 price target.